A novel hepatitis B virus genotyping system by using restriction fragment length polymorphism patterns of S gene amplicons

Guo-Bing Zeng, Shu-Juan Wen, Zhan-Hui Wang, Li Yan, Jian Sun, Jin-Lin Hou

INTRODUCTION
Hepatitis B virus (HBV) exhibits genetic variability which gives rise to the well recognized subtypes and genotypes of the virus. In addition, virus variants arise during replication as a result of nucleotide misincorporations, in the absence of any proof-reading capacity by the viral polymerase. Based on an inter-group divergence of 8% or more in the complete genome nucleotide sequence, HBV has been classified into at least 8 different genotypes[1-4]. Genotyping could also be accomplished based on partial sequences from the pre-S or S genes of the HBV genome[5-7].

HBV genotypes have distinct geographical distributions. Genotypes A and D occur frequently in Africa and Europe[5,8], while genotypes B and C are prevalent in Asia[9]. Genotype E is almost entirely restricted to Africa, and F is found preferentially in Central and South America[10]. Genotype G was reported in France and the United States[11]. Recently, the eighth genotype H has been described in Central America[12].

An increasing number of studies showed that HBV genotypes might influence HBsAg serocconversion rates[13], mutation patterns in precore and core promoter regions[14,15], severity of liver disease[16,17] and response to antiviral treatment[18]. In order to confirm and extend these observations, further studies are needed to be carried out, using reliable and simple methods for HBV genotyping. Though several HBV genotyping methods have been reported so far[15,17,18], these could identify genotypes A to F, but not G or H.

The aim of this study was therefore to establish a simple and accurate HBV genotyping system using restriction fragment length polymorphism (RFLP) of the small S gene region, which could identify HBV genotypes A to H and would be applicable to large-scale studies.

MATERIALS AND METHODS

HBV sequences and computerized analyses
Two hundred and thirty-two complete and 8 S sequences of HBV were obtained from the DNA database (GenBank), comprising 24 sequences of genotype A, 35 of B, 97 of C, 38 of D, 5 of E, 30 of F, 8 of G and 3 of H. The small S gene regions of all these sequences were aligned and analysed to identify conserved regions and restriction enzyme sites that were genotype-specific. Five restriction enzymes were deemed to be appropriate for this purpose, and restriction patterns were determined by computerized analysis of each of the above mentioned sequences. The DNAsis software package (Hitachi Software Engineering, 1991) was used in this study.

Patient sera and HBV genotypes
Serum samples from 190 Chinese patients with chronic hepatitis B were collected from 2 liver units in mainland of China, and stored at -70 °C. All subjects (male/female = 161/29, mean age = 29.5±9.16 years) were HBsAg-positive by commercially available immunoassays (Abbott Laboratories). Of them, 116 (61%) were HBeAg positive, and the mean alanine transaminase value (ALT) was 248.5±342.8 IU/L. These samples were initially genotyped by RFLP analysis of pre-S amplicons as previously described[8].

Genotyping PCR and restriction enzyme treatment
The S gene sequences were amplified by nested PCR. Based
on the most conserved regions, we designed PCR primers to amplify the sequence between nt 203 to nt 787, yielding an amplicon of 585 bp. The outer primers were PrsS2 (sense, nt 2820-2837, 5’-GGGACACCATATTCCTTGG) and SIR (antisense, nt 842-821, 5’-TTAGGGTITAAATGTATAACCA). The inner primers were YS1 (sense, nt 203-221, 5’-GGGGTTTCTTGTGTA) and YS2 (antisense, nt 787-767, 5’-GGGACTCAAGATGTGTACAG). DNA was extracted from the serum as previously described[19]. A 5 µL of the resuspended DNA was added to an amplification mixture containing 5 µL of 10× Taq polymerase buffer, 5 µL of 25 mmol/L deoxyribonucleotide triphosphates, 1 µL (2U) of Taq polymerase (Promega, Beijing, China), and 10 pmol each of primers PrsS2 and SIR (total volume of 50 µL). The PCR profile was an initial 3 min denaturation at 94°C, followed by 35 cycles of amplification including denaturation for 45 s at 94°C, annealing for 60 s at 53°C, and extension for 90 s at 72°C. Strand synthesis was completed at 72°C for 6 min. A 1 µL of the first-round PCR products was then used for the second-round PCR under the same conditions but with the primers YS1 and YS2. A 10 µL of the second-round PCR products was mixed with 0.5 µL (5U) of the chosen restriction enzyme (New England Biolabs, Hong Kong, China), 1.5 µL of 10× buffer and 3.0 µL of water. After incubation at 37°C for 4 h, the samples were electrophoresed on a 30 g/L agarose gel. A 10 µL of undigested second-round PCR products was run in parallel with the enzyme-digested samples. The restriction patterns were read visually under ultraviolet light.

**Identification of mixed genotypes**

When non-specific, atypical or mixed RFLP patterns were found, and the small S gene region was amplified with primers BS1 (sense, nt 56-76, 5’-CCTGCTGGTGGCGCCAGTTCC) and SIR, yielding an amplicon of 797-bp in length. These PCR products were purified and ligated into the pGEM-T vector using a commercial kit (Promega, Beijing, China). Ten positive clones were selected for further analysis. Extracted plasmid DNA was amplified with primers YS1 and YS2. PCR products were digested with restriction enzymes and analysed by electrophoresis. Samples that did not give clear results were then sequenced directly.

**Sequencing and sequence data analysis**

Three serum samples each of genotypes B, C and D, and 2 serum samples of genotype A by our method were randomly selected for sequencing. The small S gene region was amplified with primers BS1 and SIR and ligated into the pGEM-T vector as described above. Plasmid DNA was extracted from positive clones and sequenced using an ABI automatic DNA sequencer. Sequences were then edited, aligned and compared with reference sequences using the DNAsis software.

**RESULTS**

**Predicted RFLP patterns**

Following alignment of S gene sequences, five restriction enzymes, StyI, BsrI, DpnI, HpaII and EaeI were deemed to be suitable for yielding restriction patterns that would identify all eight HBV genotypes.

Genotype C had a StyI site at nt position 455, cutting the S gene into two fragments of 253- and 332-bp in length. This restriction pattern was found in 95 of 97 genotype C sequences examined. This restriction site was absent in all other genotypes. All genotype B sequences could be distinguished by the fact that the S gene had a unique BsrI site at nt position 328, which gave two characteristic bands of 126- and 459-bp in length. A BsrI site at nt position 502 was observed in 22 of 24 genotype A and all genotype E and G sequences. Moreover, genotype E PCR products could be digested at position 706 by HpaII, while genotype G had no EaeI site, which was present in all other genotypes. The BsrI site at nt position 502 was also found in 1 of 38 genotype D sequences, which could be mistaken as genotype A. Thus the sequences which still left unresolved were those of genotypes D, F and H. For genotype F, a DpnI site was found at nt positions 491 and 747, while genotypes D and H were cut at nt position 491 but not at 747. Finally, a HpaII site at nt position 292 in genotype H could be differentiated from genotype D. The sequences recognized by these enzymes are shown in Figure 1. The patterns created by these enzymes from the small S gene region are shown in Table 1.

**Strategy for HBV genotyping using the new method**

The optimal strategy, using the new method, which could be applied to a particular geographical region according to the most prevalent HBV genotype in that region, is summarized in Figure 2. For example, genotypes B and C were the most prevalent in the Far East. After parallel digestion by BsrI and

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>Pattern</th>
<th>No. of sequences</th>
<th>Fragments obtained</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bsrl</td>
</tr>
<tr>
<td>A</td>
<td>A1</td>
<td>12</td>
<td>300 285</td>
</tr>
<tr>
<td>A2</td>
<td>10</td>
<td>300 285</td>
<td>585</td>
</tr>
<tr>
<td>A3</td>
<td>1</td>
<td>585</td>
<td>585</td>
</tr>
<tr>
<td>A4</td>
<td>1</td>
<td>585</td>
<td>585</td>
</tr>
<tr>
<td>B</td>
<td>B1</td>
<td>33</td>
<td>126 459</td>
</tr>
<tr>
<td>B2</td>
<td>2</td>
<td>126 184 275</td>
<td>585</td>
</tr>
<tr>
<td>C</td>
<td>C1</td>
<td>95</td>
<td>585</td>
</tr>
<tr>
<td>C2</td>
<td>2</td>
<td>585</td>
<td>585</td>
</tr>
<tr>
<td>D</td>
<td>D1</td>
<td>36</td>
<td>585</td>
</tr>
<tr>
<td>D2</td>
<td>1</td>
<td>585</td>
<td>585</td>
</tr>
<tr>
<td>D3</td>
<td>1</td>
<td>300 285</td>
<td>585</td>
</tr>
<tr>
<td>E</td>
<td>E1</td>
<td>4</td>
<td>300 285</td>
</tr>
<tr>
<td>E2</td>
<td>1</td>
<td>126 174 285</td>
<td>585</td>
</tr>
<tr>
<td>F</td>
<td>F1</td>
<td>29</td>
<td>585</td>
</tr>
<tr>
<td>F2</td>
<td>1</td>
<td>585</td>
<td>289 296</td>
</tr>
<tr>
<td>G</td>
<td>G1</td>
<td>8</td>
<td>300 285</td>
</tr>
<tr>
<td>H</td>
<td>H1</td>
<td>3</td>
<td>585</td>
</tr>
</tbody>
</table>
more than 90% of the serum samples from Chinese patients could be genotyped.

Comparison with genotyping by RFLP of PreS1 regions

Of the 190 serum samples, 3 were HBV DNA negative by nested PCR. Thus, 187 serum samples were analysed in this study, and compared to the results obtained by RFLP analysis of the pre-S1 region. One hundred and eight-one of the 187 serum samples were classified as genotypes A (2), B (95), C (75) and D (9). These results were in full agreement with those obtained with our new method. Because of nonspecific amplification and atypical restriction patterns, 6 samples could not be classified by RFLP analysis of pre-S1 amplicons. However, these were resolved into either genotypes B (2), C (1) or mixed B+C (3) by

Figure 1 Genotype-specific sites recognized by restriction enzymes. GeneBank accession numbers and consensus sequences from HBV genotypes A to H are listed. The shaded letters indicate the sequences recognized by the relevant enzyme. StyI recognizes sequence C|C (A/T) (A/T) GG; BsrI, C|CAGT; DpnI, GA|TC; HpaII, C|CGG; EaeI, (C/T) |GGCC (A/G). *nt position number is from the unique EcoRI site according to the reference sequence x001587 (genotype C).

Figure 2 Diagrammatic representation of the position of PCR primers and RFLP analyses for HBV genotyping. The second round PCR products, which were 585 bp, were digested by (1) BsrI, (2) StyI, (3) DpnI, (4) HpaII and (5) EaeI. Genotypes B and C could be typed in one step using parallel digestion with BsrI and StyI.
our method after cloning and repeat RFLP analysis. These results were verified subsequently by direct sequencing of the S gene. Thus the final genotype distribution of the samples was A, 2 (1.1%); B, 97 (51.9%); C, 76 (40.6%); D, 9 (4.8%) and mixed (genotypes B and C), 3 (1.6%). Examples of RFLP analysis using the new method are shown in Figure 3.

**Verification of reliability of the new method**

Nucleotide sequences of 11 samples randomly selected were determined and then compared to reference sequences for genotypes A (X02763), B (D00329), C (X01587) and D (X59795). The homologies of the S gene region under investigation were 97.9-98.3%, 99.3-99.9%, 97.5-98.8% and 98.2-98.5%, respectively, which confirmed the validity of the new RFLP technique.

**DISCUSSION**

Great importance has been attached to the differences between HBV genotypes. In earlier studies, a higher frequency of liver dysfunction was observed in patients with subtype adw (mainly genotype C) compared to those with subtype ayw. These findings concurred with those reported by Lindh et al. and Orito et al.. Mayerat et al. found that genotype A was more frequent in chronic hepatitis B patients than genotype D, while the opposite situation was true in acute hepatitis B patients. A study from Taiwan reported that genotype C was associated with more active liver disease compared to genotype B, and this was supported by a more recent study.. A retrospective study of 332 cases showed that patients with HBV genotype B had a lower prevalence and earlier seroconversion to anti-HBe than those with genotype C, which could explain the less active liver disease seen in patients with genotype B. Another study suggested that HBV genotype might influence HBV recurrence after liver transplantation as patients with genotype D appeared to have a higher risk for HBV recurrence and mortality. The correlation between HBV genotype and response to interferon therapy has also been reported. HBV genotype C was associated with a higher frequency of core promoter mutation and a lower response rate to interferon alfa therapy..

Hou et al. studied 103 chronic hepatitis B patients from 16 European centers and found that HBV genotype A responded better to standard interferon treatment than other genotypes. This appeared to be related to its molecular characteristics, having a greater tendency to develop core promoter mutations and less variation in the nucleocapsid protein. A study reported that patients carrying the adw subtype were associated with a higher risk of lamivudine resistance than those with ayw subtype, although Chan et al. found that HBcAg seroconversion after treatment by lamivudine was not influenced by the HBV genotype. To interpret these differences between HBV genotypes, larger-scale investigations are needed. So, development of accurate, simple and inexpensive HBV genotyping methods would be very useful in this respect.

Several methods have been used for HBV genotyping including direct sequencing, RFLP, PCR with genotype-specific primers, line probe assay and enzyme-linked immunosorbent assay (ELISA). Genotyping based on complete genome sequences is an ideal method, but sequencing is costly and cannot be easily carried out in clinical diagnostic laboratories for large-scale studies. Currently, PCR-RFLP is the most widely used method for HBV genotyping because it is simple and inexpensive. Norder et al. found that HBV genotyping could be accomplished based on the sequence of the S gene. After analyzing 73 HBV sequences from GeneBank, Lindh et al. developed a genotyping method based on RFLP patterns of a S gene amplicon, which first identified HBV genotypes A-F. They also reported another genotyping technique based on RFLP analysis of the pre-S region. However, pre-S gene was less suitable for genotyping than S gene because it was not so conserved as S gene.

Mizokami et al. compared 68 complete and 106 small S HBV sequences and confirmed that S gene could be used to accurately identify the six HBV genotypes A-F. They also described a RFLP genotyping system using five enzymes, HpaII, NciI, AlwI, EarI, and NalI. Because genotypes G and H were not discovered then, they could not be assessed by these methods. Compared with previous methods, our new method has several relative advantages. Firstly, it can identify all eight HBV genotypes. Secondly, it is more accurate because it was based on analyzing many of the sequences deposited in GeneBank. Thirdly, a simple and inexpensive strategy can be adopted according to the most prevalent HBV genotypes in a particular geographical region. For example, the strategy shown in Figure 2 was especially suitable for the Far East where genotypes B and C are mostly found. The RFLP patterns are simple, with one or two bands, and therefore easy to be recognized.

In this study, a new method for HBV genotyping based on RFLP analysis of S gene amplicons was established, and could identify all eight HBV genotypes. This HBV genotyping system is accurate, simple and can be expected to be widely used in studies of HBV genotyping.

**REFERENCES**


2. Norder H, Courouce AM, Magnus LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new
hepatitis B viruses of genotypes B and C. Japan HBV genotype study for clinical and molecular biological differences between Ichida T, Okanoue T, Yotsuyanagi H, Iino S. A case-control study for hepatitis B virus genotype A confer a higher response rate to interferon therapy. J Hepatol 2001; 33: 430-439


Chan HLY, Wong ML, Hui AY, Chim AML, Tse AML, Hung LCT, Chan FKL, Sung JYJ. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9: 2695-2697


Edited by Zhang JZ and Wang XL. Proofread by Xu FM